Biology subjects

Catterson, J. H.

Publications and source records attributed to Catterson, J. H..

8 recordsLinked to original sources

bioRxiv2026

Sexually dimorphic behavioural signatures of tau toxicity in adult Drosophila

Tau pathology is central to Alzheimers disease and related tauopathies, yet mechanisms driving neuronal dysfunction and degeneration downstream of pathological changes in tau remain poorly understood. Drosophila melanogaster models provide a genetically tractable system with an intact nervous system and short lifespan that allows investigation of mechanisms of many diseases. However, in Drosophila, developmental expression of human tau frequently causes lethality and developmental phenotypes, limiting the study of neurodegenerative disease processes. Further, sex is rarely considered in Drosophila studies of tau pathology despite clear sex differences being observed in many aspects of human tauopathies. Here, we used an inducible, pan-neuronal GeneSwitch system to express human tau isoforms exclusively in adulthood, enabling the dissection of tau toxicity independent of development. We combined longitudinal behavioural monitoring with lifespan and neurodegeneration analyses, and performed a targeted genetic screen to identify modifiers of tau-induced dysfunction. Adult-onset tau expression produced striking, sexually dimorphic effects on survival and behaviour. Neuronal expression of the human tau isoform with 4 microtubule binding repeats and neither alternatively spliced N-terminal exon (0N4R tau) caused pronounced neurodegeneration and reduced lifespan, which was exacerbated in flies expressing the phospho-mimetic 0N4R-TauE14 variant. Tau expression produced sexually dimorphic effects on survival and behaviour, with females exhibiting a greater reduction in lifespan, while the induction-dependent increase in vacuolar neurodegeneration was broadly comparable between sexes. Behaviourally, tau expression induced elevated daytime inactivity in females, whereas males exhibited hyperactivity, revealing opposing functional outcomes between sexes. A targeted genetic screen further identified modifiers of tau-dependent behavioural impairment. APOE2 expression in glia, syndecan overexpression in neurons, and increased global expression of the chaperone heat shock protein 90 all reduced 0N4R-TauE14-induced behavioural changes. Seventeen candidate perturbations enhanced the TauE14-induced behavioural phenotype, including manipulations of APOE3, CLU, INPP5D/INPP5K, BIN1/Amph, synaptogyrin, LRP1, NPC1, and Hsp90 pathways. Together, these findings establish an adult-onset Drosophila model of tauopathy that uncouples neurotoxicity from development, reveals sex as a major determinant of tau-induced behavioural outcomes in flies, and uncovers genetic modulators of tau-induced dysfunction. This work highlights the importance of incorporating sex as a biological variable and provides a platform for mechanistic and translational studies of tauopathy.

neuroscience↗

bioRxiv2024

Drosophila appear resistant to trans-synaptic tau propagation

Alzheimers disease (AD) is the most common cause of dementia in the elderly, prompting extensive efforts to pinpoint novel therapeutic targets for effective intervention. Among the hallmark features of AD is the development of neurofibrillary tangles comprised of hyperphosphorylated tau protein, whose progressive spread throughout the brain is associated with neuronal death. Trans-synaptic propagation of tau has been observed in mouse models and indirect evidence for tau spread via synapses has been observed in human AD. Halting tau propagation is a promising therapeutic target for AD, thus a scalable model system to screen for modifiers of tau spread would be very useful for the field. To this end, we sought to emulate the trans-synaptic spread of human tau (hTau) in Drosophila melanogaster. Employing the trans-Tango circuit mapping technique, we investigated whether tau spreads between synaptically connected neurons. Immunohistochemistry and confocal imaging were used to look for tau propagation. Examination of hundreds of flies expressing 4 different human tau constructs in two distinct neuronal populations reveal a robust resistance in Drosophila to the trans-synaptic spread of hTau. This resistance persisted in lines with concurrent expression of amyloid-{beta}, in lines with global hTau knock-in to provide a template for human tau in downstream neurons, and with manipulations of temperature. These negative data are important for the field as we establish that Drosophila expressing human tau in subsets of neurons are unlikely to be useful to perform screens to find mechanisms to reduce the trans-synaptic spread of tau. The inherent resistance observed in Drosophila may serve as a valuable clue, offering insights into strategies for impeding tau spread in future studies.

neuroscience↗

bioRxiv2024

Opposing roles of physiological and pathological amyloid-β on synapses in live human brain slice cultures

In Alzheimers disease, it is theorised that amyloid beta (A{beta}) and tau pathology contribute to synapse loss. However, there is limited information on how endogenous levels of tau and A{beta} protein relate to patient characteristics, or how manipulating physiological levels of A{beta} impacts synapses, in living adult, human brain. Here, we employed live human brain slice cultures as a translational tool to assess endogenous tau and A{beta} release, pathology, and response to experimental manipulation. We found that the levels of A{beta}1-40 and tau detected in the culture medium depend on donor age, and brain region, respectively. Pharmacologically raising physiological A{beta} concentration enhanced levels of synaptic transcripts. Treatment of slices with A{beta}-containing Alzheimers disease brain extract resulted in postsynaptic A{beta} uptake and loss of presynaptic puncta. These data indicate that physiological and pathological A{beta} can have opposing effects on synapses in living human brain tissue.

neuroscience↗

bioRxiv2023

Tau phosphorylated at serine 356 is associated with Alzheimer's disease pathology and can be lowered in mouse and human brain tissue using the NUAK inhibitor WZ4003

Tau hyperphosphorylation and aggregation is a common feature of many dementia-causing neurodegenerative diseases. Tau can be phosphorylated at up to 85 different sites, and there is increasing interest in whether tau phosphorylation at specific epitopes, by specific kinases, plays an important role in disease progression. The AMP-activated protein kinase (AMPK) related enzyme NUAK1 been identified as a potential mediator of tau pathology, whereby NUAK1-mediated phosphorylation of tau at Ser356 prevents the degradation of tau by the proteasome, further exacerbating tau hyperphosphorylation and accumulation. This study provides a detailed characterisation of the association of p-tau Ser356 with progression of Alzheimers disease pathology, identifying a Braak stage-dependent increase in p-tau Ser356 protein levels and an almost ubiquitous presence in neurofibrillary tangles. We also demonstrate, using sub-diffraction-limit resolution array tomography imaging, that p-tau Ser356 co-localises with synapses in AD post-mortem brain tissue, increasing evidence that this form of tau may play important roles in AD progression. To assess the potential impacts of pharmacological NUAK inhibition in an ex vivo system that retains multiple cell types and brain-relevant neuronal architecture, we treated postnatal mouse organotypic brain slice cultures from wildtype or APP/PS1 littermates with the commercially available NUAK1/2 inhibitor WZ4003. Whilst there were no genotype specific effects, we found that WZ4003 results in a culture-phase dependent loss of total tau and p-tau Ser356, which corresponds with a reduction in neuronal and synaptic proteins. By contrast, application of WZ4003 to live human brain slice cultures results in a specific lowering of p-tau Ser356, alongside increased neuronal tubulin protein. This work identifies differential responses of postnatal mouse organotypic brain slice cultures and adult human brain slice cultures to NUAK1 inhibition that will be important to consider in future work developing tau-targeting therapeutics for human disease.

neuroscience↗

bioRxiv2022

Inhibition of S6K lowers age-related inflammation and immunosenescence and increases lifespan through the endolysosomal system

The nutrient-sensing Target of Rapamycin complex 1 (TORC1) is an evolutionarily conserved regulator of longevity and healthspan. S6 kinase (S6K) is an essential downstream mediator for the effect of TORC1 on longevity. However, mechanistic insights on how TORC1-S6K signalling promotes lifespan and healthspan are still limited. Here we show that activity of S6K in the Drosophila fat body is essential for rapamycin-mediated longevity. Fat-body-specific activation of S6K blocked lifespan extension upon rapamycin feeding and induced accumulation of multilamellar lysosomal enlargements. By proteomics analysis we identified Syntaxin 13 (Syx13) as an important downstream mediator of TORC1-S6K signalling involved in regulating lysosomal morphology. Inhibition of TORC1-S6K signalling decreased age-associated hyperactivation of the NF-{kappa}B-like IMD pathway in the fat body and promoted bacterial clearance, mediated by Syx13, suggesting that lysosomal and immune function are connected during ageing. Middle-age-onset repression of IMD pathway in the fat body by Relish RNAi promoted bacteria clearance and extended fly lifespan. In mice, chronic rapamycin treatment elevated Syntaxin 12/13 (Stx12) level in liver. We identified alleviated immune processes in the aged liver as a common signature of S6K1-deficient and rapamycin-treated mice. Thus, our results indicate that suppression of the TORC1-S6K-Syx13 axis ameliorates both inflammageing and immunosenescence in hepatic tissues via the endolysosomal system and thereby extends longevity, providing a mechanistic explanation for the effects of rapamycin and suppression of S6K on immune function and lifespan in model organisms and, potentially, humans.

genetics↗

bioRxiv2021

Sexual identity of enterocytes regulates rapamycin-mediated intestinal homeostasis and lifespan extension

Pharmacological attenuation of mTOR by rapamycin and other compounds presents a promising route for delay of ageing-related pathologies, including intestinal cancers. Here, we show that rapamycin treatment in Drosophila extends lifespan in females but not in males. Female-specific, age-related gut pathology and impaired intestinal barrier function are both markedly slowed by rapamycin treatment, mediated by increased autophagy. Upon rapamycin treatment, female intestinal enterocytes increase autophagy, via the H3/H4 histone-Bchs axis, while male enterocytes show high basal levels of autophagy that do not increase further upon rapamycin treatment. Sexual identity of enterocytes alone, determined by the expression of transformerFemale, dictates sexually dimorphic cell size, H3/H4-Bchs expression, basal rates of autophagy, fecundity, intestinal homeostasis and extension of lifespan in response to rapamycin. This study highlights that tissue sex determines regulation of metabolic processes by mTOR and the efficacy of mTOR-targeted, anti-ageing drug treatments.

physiology↗

bioRxiv2021

Aβ toxicity rescued by protein retention in the ER

Accumulation of A{beta} in the brain is one of the hallmarks of Alzheimers disease (AD). In the adult Drosophila brain, human A{beta} over-expression is toxic and leads to deterioration of climbing ability and shortened lifespan. However, it remains unknown if A{beta} is inherently toxic or if it triggers toxic downstream pathways that lead to neurodegeneration. Here, we describe a novel, and previously unidentified, protective role of intracellular laminin chain accumulation. Despite high A{beta} levels, over-expression of the extracellular matrix protein subunit Laminin B1 (LanB1) resulted in a robust rescue of toxicity, highlighting a potential protective mechanism of resistance to A{beta}. Over-expression of other Laminin subunits and a Collagen IV subunit also significantly rescued A{beta} toxicity, while combining LanB1 with these subunits led to an even larger rescue. Imaging revealed that LanB1 was retained in the ER but had no effect on the secretion of A{beta} into the extracellular milieu. LanB1 rescued toxicity independently of the IRE1/XBP1-mediated branch of the ER stress response. Interestingly, over-expression of ER-targeted GFP also rescued A{beta} toxicity, indicating a potentially broader benefit of ER protein retention. Finally, in proof-of-principle lentiviral transduction experiments using murine organotypic hippocampal slice cultures, over-expression of mouse Lamb1 resulted in ER-retention in transduced cells, highlighting a conserved mechanism. Typically, retention of proteins in the ER is detrimental to cellular health, but in the context of neuronal A{beta} toxicity it may prove to be beneficial and a new therapeutic avenue for AD.

neuroscience↗

bioRxiv2021

TMEM97 increases in synapses and is a potential synaptic Aβ binding partner in human Alzheimer's disease

Synapse loss correlates with cognitive decline in Alzheimers disease, and soluble oligomeric amyloid beta is implicated in synaptic dysfunction and loss. An important knowledge gap is the lack of understanding of how amyloid beta leads to synapse degeneration. In particular, there has been difficulty in determining whether there is a synaptic receptor that binds amyloid beta and mediates toxicity. While many candidates have been observed in model systems, their relevance to human AD brain remains unknown. This is in part due to methodological limitations preventing visualization of amyloid beta binding at individual synapses. To overcome this limitation, we combined two high resolution microscopy techniques: array tomography and Forster resonance energy transfer (FRET) to image over 1 million individual synaptic terminals in temporal cortex from AD (n=9) and age matched control cases (n=6). Within postsynaptic densities, amyloid beta generates a FRET signal with transmembrane protein 97, cellular prion protein, and postsynaptic density 95. Transmembrane protein 97 is also present in a higher proportion of postsynapses in Alzheimers brain compared to controls. Further, we inhibited amyloid beta / transmembrane protein 97 interaction in a mouse model of amyloidopathy by treating with the an allosteric modulator CT1812 or vehicle. CT1812 drug concentration correlated negatively with synaptic FRET signal between transmembrane protein 97 and amyloid beta. In human induced pluripotent stem cell derived neurons challenged with human Alzheimers brain homogenate, transmembrane protein 97 and amyloid beta are present in synapses. Transcriptional changes are induced by A{beta} including changes in genes involved in neurodegeneration and neuroinflammation. CT1812 treatment of these neurons caused changes in gene sets involved in synaptic function. These data support a role for transmembrane protein 97 in the synaptic binding of amyloid beta in human Alzheimers disease brain where it may mediate synaptotoxicity.

neuroscience↗